Aligos Therapeutics, Inc. Common Stock ALGS

$6.76 +2.81% at last close

Recent SEC Filings

FormDescriptionFiledDocument
10-Q 10-Q 2026-08-06 View →
8-K FORM 8-K 2026-08-06 View →
4 Insider transaction 2026-06-29 View →
4 Insider transaction 2026-06-29 View →
4 Insider transaction 2026-06-29 View →
4 Insider transaction 2026-06-29 View →
4 Insider transaction 2026-06-29 View →
4 Insider transaction 2026-06-29 View →
8-K 8-K 2026-06-26 View →
10-Q 10-Q 2026-05-07 View →
8-K FORM 8-K 2026-05-07 View →
DEF 14A DEF 14A 2026-04-29 View →
8-K 8-K 2026-04-21 View →
8-K 8-K 2026-04-14 View →
4 Insider transaction 2026-03-11 View →
4 Insider transaction 2026-03-11 View →
4 Insider transaction 2026-03-11 View →
4 Insider transaction 2026-03-11 View →
10-K 10-K 2026-03-05 View →
8-K FORM 8-K 2026-03-05 View →
8-K 8-K 2026-02-04 View →
10-Q 10-Q 2025-11-06 View →
8-K FORM 8-K 2025-11-06 View →
10-Q 10-Q 2025-08-06 View →
8-K FORM 8-K 2025-08-06 View →
4 Insider transaction 2025-07-18 View →
4 Insider transaction 2025-07-18 View →
4 Insider transaction 2025-07-18 View →
4 Insider transaction 2025-06-26 View →
4 Insider transaction 2025-06-26 View →
4 Insider transaction 2025-06-26 View →
4 Insider transaction 2025-06-26 View →
4 Insider transaction 2025-06-26 View →
4 Insider transaction 2025-06-26 View →
8-K 8-K 2025-06-26 View →
10-Q 10-Q 2025-05-06 View →
8-K FORM 8-K 2025-05-06 View →
DEF 14A DEF 14A 2025-04-28 View →
S-3 S-3 2025-03-27 View →
10-K 10-K 2025-03-10 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$6.76
Market Cap
$41.06 million
52-Week Range
$3.98 – $13.69
Average Volume
150K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.